CHANNELS

Subscribe to the InfoTech eNewsletter

infoTECH News

TMCNet:  OncoSec Medical to Present Corporate Update at Biotech Showcase 2014

[January 07, 2014]

OncoSec Medical to Present Corporate Update at Biotech Showcase 2014

SAN DIEGO --(Business Wire)--

OncoSec Medical Inc. (OTCQB: ONCS), a biotechnology company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced that Punit Dhillon, President and CEO, will provide a corporate update at Biotech Showcase 2014; one of the world's largest life sciences conferences held annually in San Francisco.

The presentation is scheduled to take place on Tuesday, January 14 at 2:30 p.m. PST at the Parc 55 Wyndham San Francisco-Union Square, located at 55 Cyril Magnin Street. A live webcast will be available by visiting the following link: http://www.media-server.com/m/p/byw47js4.

About Biotech Showcase 2014

Biotech Showcase™ is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this critical week, which is widely viewed as setting the tone for the coming year.

Now in its sixth yar, Biotech Showcase is expected to attract upwards of 1,700 attendees. The program includes lunch plenary sessions featuring top industry leaders and innovators speaking on industry and time-relevant topics, as well as presentations from both private and public companies.

About OncoSec Medical Inc.

OncoSec Medical Inc. is�a biopharmaceutical company�developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors.�ImmunoPulse and NeoPulse therapies�address an unmet medical need.�They represent�a potential solution, for less invasive and less expensive therapies and can potentially minimize the detrimental effects of current cancer treatments such as surgery, systemic chemotherapy and other treatment alternatives. OncoSec Medical's core technology is based on its proprietary�use of an�electroporation platform to enhance�the�delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent�(NeoPulse). Treatment of�various solid cancers�using these targeted�anti-cancer agents�has demonstrated�selective destruction of cancerous cells�while potentially sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. More information is available at�http://www.oncosec.com/.

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward-looking statements." Forward-looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.


[ InfoTech Spotlight's Homepage ]


blog comments powered by Disqus

FOLLOW US

Subscribe to InfoTECH Spotlight eNews

InfoTECH Spotlight eNews delivers the latest news impacting technology in the IT industry each week. Sign up to receive FREE breaking news today!
FREE eNewsletter